Santarus Announces Pricing of Secondary Common Stock Offering by a Selling Stockholder

  Santarus Announces Pricing of Secondary Common Stock Offering by a Selling
  Stockholder

Business Wire

SAN DIEGO -- May 10, 2013

Santarus, Inc. (NASDAQ: SNTS) today announced the pricing of a secondary
underwritten public offering of 4,250,000 shares of its common stock at a
price to the public of $18.25 per share. All shares were offered by Cosmo
Technologies Limited. The selling stockholder has granted the underwriter an
option for 30 days to purchase up to 637,500 additional shares of common
stock. Santarus will not sell any shares or receive any proceeds from the
offering. The offering is expected to close on May 15, 2013, subject to the
satisfaction of customary closing conditions.

Jefferies LLC is acting as the sole book-running manager for the offering.

A shelf registration statement (including a prospectus) relating to these
securities was filed by Santarus with the Securities and Exchange Commission
(SEC) and declared effective by the SEC on April 29, 2009. A final prospectus
supplement and the accompanying prospectus related to the offering will be
filed with the SEC and will be available on the SEC’s website located at
http://www.sec.gov. Copies of the final prospectus supplement and the
accompanying prospectus relating to this offering, when available, may be
obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 12th floor, New York, NY 10022 or by telephone
at 877-547-6340 or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.

About Santarus

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring,
developing and commercializing proprietary products that address the needs of
patients treated by physician specialists. The company's current commercial
efforts are focused on five products. UCERIS^™ ^ (budesonide) extended release
tablets for the induction of remission in patients with active, mild to
moderate ulcerative colitis and ZEGERID^® (omeprazole/sodium bicarbonate) for
the treatment of certain upper gastrointestinal disorders are promoted to
gastroenterologists. GLUMETZA^® (metformin hydrochloride extended release
tablets) and CYCLOSET^® (bromocriptine mesylate) tablets, which are indicated
as adjuncts to diet and exercise to improve glycemic control in adults with
type 2 diabetes, and FENOGLIDE^® (fenofibrate) tablets, which is indicated as
an adjunct to diet to reduce high cholesterol, are promoted to
endocrinologists and other physicians who treat patients with type 2 diabetes.
Full prescribing and safety information for Santarus’ products is available at
www.santarus.com.

Santarus’ product development pipeline includes the investigational drug
RUCONEST^® (recombinant human C1 esterase inhibitor). A Biologics License
Application for RUCONEST was submitted to the FDA in April 2013 for the
treatment of acute angioedema attacks in patients with hereditary angioedema.
Santarus is also developing rifamycin SV MMX^®, which is in Phase III clinical
testing for the treatment of travelers’ diarrhea. In addition, the company has
completed a Phase I clinical program with SAN-300, an investigational
monoclonal antibody. More information about Santarus is available at
www.santarus.com.

Forward-Looking Statements

Santarus cautions you that statements included in this press release that are
not a description of historical facts are forward-looking statements. Such
forward-looking statements include statements about Santarus’ expectations
with respect to the closing of the offering by the selling stockholder. The
inclusion of forward-looking statements should not be regarded as a
representation by Santarus that any of its plans will be achieved. Actual
results may differ materially from those set forth in this release due to the
risks and uncertainties associated with market conditions and the satisfaction
of customary closing conditions related to the offering, as well as risks and
uncertainties inherent in Santarus’ business, including, without limitation,
difficulties or delays in development, testing, manufacturing and marketing
of, and obtaining and maintaining regulatory approvals for, Santarus’ products
and other risks detailed in Santarus’ prior press releases as well as in
public periodic filings with the SEC, including its Quarterly Report on Form
10-Q for the quarter ended March 31, 2013.

You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary statement and
Santarus undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as may be
required by applicable law. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation Reform Act of
1995.

Santarus^®, FENOGLIDE^®, UCERIS^™, and ZEGERID^® are trademarks of Santarus,
Inc. GLUMETZA^® is a trademark of Biovail Laboratories International S.r.l.
licensed exclusively in the United States to Depomed, Inc. CYCLOSET^® is a
trademark of VeroScience LLC. MMX^® is a trademark of Cosmo Technologies
Limited. RUCONEST^® is a trademark of Pharming Group N.V.

Contact:

COMPANY CONTACT:
Santarus, Inc.
Martha L. Hough
VP Finance & Investor Relations
(858) 314-5824
Debra P. Crawford
Chief Financial Officer
(858) 314-5708
or
INVESTOR CONTACT:
Westwicke Partners, LLC
Stefan Loren, Ph.D. (sloren@westwicke.com)
(858) 356-5930
Robert Uhl (robert.uhl@westwicke.com)
(858) 356-5932
 
Press spacebar to pause and continue. Press esc to stop.